

the Examiner examine the claims with regard to each of SEQ ID NOs: **59-63**, since this search would be no more burdensome than a search of SEQ ID NOs: 59 and 61 alone.

**Preliminary Amendment**

Prior to examining the elected claims on the merits, please amend the application as follows.

**In the Claims:**

Please cancel claims 2, ~~8-15~~ and 19-23, without prejudice to including the subject matter of the canceled claims in one or more additional patent applications.

Please amend claims 1, 3, and 4 to read as follows. For the Examiner's convenience a "**Marked-Up Copy of Claims Amended in Response to Restriction Requirement and Preliminary Amendment**" accompanies this page. In that document, text which has been added to the claims is underlined, and text which has been deleted from the claims is struck through.

*sub B1*  
1. (Amended) An isolated nucleic acid molecule selected from the group consisting of:

*A*

- a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of any one of SEQ ID NO: 59, SEQ ID NO: 60, and the nucleotide sequence of a cDNA clone deposited with ATCC® as Accession number PTA-151, or a complement thereof;
- b) a nucleic acid molecule comprising at least 400 nucleotide residues and having a nucleotide sequence identical to at least 400 consecutive nucleotide residues of any one of SEQ ID NO: 59, SEQ ID NO: 60, and the nucleotide sequence of a cDNA clone deposited with ATCC® as Accession number PTA-151, or a complement thereof;